Interview: KoBioLabs Pioneering The Microbiome Landscape In Korea
Executive Summary
Industry interest in the development of microbiome modulators is noticeably increasing worldwide. In South Korea, KoBioLabs is leading the charge to microbiome drug development, helped by a sizable database and biobank. Its founder and CEO GwangPyo Ko talked to Scrip about its core technology, pipeline progress, and general strategy.
You may also be interested in...
KoBioLabs Sees IPO Building Its Credentials As Global Microbiome Player
The Korean microbiome therapeutics developer KoBioLabs will launch a domestic IPO later this month and hopes to grow into a top three global company in the sector by 2025, helped by licensing deals.
Kanaph CEO On Surviving The Biotech Funding 'Barley Hump'
The CEO of Korean bioventure Kanaph Therapeutics, Byoung Chul Lee, talks to Scrip about the difficulties such companies are going through amid generally weak investor sentiment, as well as the company's own financing and R&D plans.
Emocog Setting The Standard For Cognitive Decline DTx in Korea
In a little over two years, the Korean bio-digital healthcare platform company Emocog has moved its digital therapeutic for mild cognitive impairment into pivotal clinical trials and is discussing possible collaborations with big pharma firms, CEO Yoo Hun Noh tells Scrip.